Global Search

Search articles, concepts, and chapters

Br J OphthalmolMay 20197 citations

Retinal haemangioblastoma associated with peripheral non-perfusion: widefield fluorescein angiography analysis of 41 cases.

Dalvin Lauren A, Yu Michael D, Ancona-Lezama David Arturo, Pulido Jose S, Olsen Timothy W, Shields Carol L


AI Summary

This study found peripheral retinal non-perfusion in 34% of retinal haemangioblastoma cases, especially with larger, more peripheral tumors in younger VHL patients, increasing neovascularization and vision loss risk.

Abstract

Aims

To investigate the association of peripheral retinal non-perfusion with retinal haemangioblastoma.

Methods

Medical and widefield fluorescein angiography records of patients diagnosed with retinal haemangioblastoma from 1990 to 2018 were reviewed for patient demographics, tumour features, fluorescein angiography features and characteristics of peripheral retinal non-perfusion.

Results

There were 41 eyes of 40 patients with retinal haemangioblastoma imaged by widefield fluorescein angiography during this time period. Of 41 eyes, 14 (34%) had haemangioblastoma-associated peripheral retinal non-perfusion on fluorescein angiography. A comparison of eyes with versus without non-perfusion revealed younger mean age at presentation (28 vs 43 years old, p=0.05), increased prevalence of von Hippel-Lindau (VHL) disease (62% vs 22%, p=0.01), greater mean largest tumour basal diameter (3.7 vs 2.5 mm, p=0.04), greater tumour distance from optic nerve (8.4 vs 1.9 mm, p<0.01) and increased prevalence of vascular leakage from the tumour (86% vs 52%, p=0.03). After mean follow-up of 97 versus 71 months (p=0.52), eyes with non-perfusion were significantly more likely to develop neovascularisation (40% vs 0%, p<0.01) and experience a three-line or greater decrease in visual acuity (60% vs 11%, p<0.01).

Conclusion

Peripheral retinal non-perfusion can be associated with retinal haemangioblastoma, and could be more common with larger, more peripheral tumours in younger patients with VHL disease. Eyes with haemangioblastoma-associated peripheral non-perfusion could be more likely to develop neovascularisation and lose visual acuity.


MeSH Terms

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleFluorescein AngiographyHemangioblastomaHumansInfantMaleMiddle AgedRetinaRetinal NeoplasmsRetinal VesselsVisual AcuityYoung Adult

Key Concepts6

Of 41 eyes of 40 patients with retinal haemangioblastoma imaged by widefield fluorescein angiography, 14 (34%) had haemangioblastoma-associated peripheral retinal non-perfusion on fluorescein angiography.

DiagnosisCase seriesRetrospective Case Seriesn=41 eyes of 40 patientsCh5Ch22

Eyes with retinal haemangioblastoma and peripheral retinal non-perfusion had a younger mean age at presentation (28 years old) compared to eyes without non-perfusion (43 years old, p=0.05).

PrognosisCase seriesRetrospective Case Seriesn=41 eyes of 40 patientsCh5Ch22

Eyes with retinal haemangioblastoma and peripheral retinal non-perfusion had an increased prevalence of von Hippel-Lindau (VHL) disease (62%) compared to eyes without non-perfusion (22%, p=0.01).

PrognosisCase seriesRetrospective Case Seriesn=41 eyes of 40 patientsCh5Ch22

Eyes with retinal haemangioblastoma and peripheral retinal non-perfusion had a greater mean largest tumour basal diameter (3.7 mm) compared to eyes without non-perfusion (2.5 mm, p=0.04).

PrognosisCase seriesRetrospective Case Seriesn=41 eyes of 40 patientsCh5Ch22

Eyes with retinal haemangioblastoma and peripheral retinal non-perfusion were significantly more likely to develop neovascularisation (40%) compared to eyes without non-perfusion (0%, p<0.01) after a mean follow-up of 97 versus 71 months.

PrognosisCase seriesRetrospective Case Seriesn=41 eyes of 40 patientsCh5Ch7Ch22

Eyes with retinal haemangioblastoma and peripheral retinal non-perfusion were significantly more likely to experience a three-line or greater decrease in visual acuity (60%) compared to eyes without non-perfusion (11%, p<0.01) after a mean follow-up of 97 versus 71 months.

PrognosisCase seriesRetrospective Case Seriesn=41 eyes of 40 patientsCh5Ch7Ch22

Is this article assigned to the wrong chapter(s)? Let us know.